Who is sponsoring NCT06954246?

NCT06954246 is sponsored by Qilu Pharmaceutical Co., Ltd..

What drugs are being tested in NCT06954246?

Interventions in NCT06954246: MHB088C for Injection, Topotecan, Irinotecan, Paclitaxel.

What condition does NCT06954246 study?

NCT06954246 studies Small Cell Lung Cancer Extensive Stage.

Is NCT06954246 still recruiting?

NCT06954246 is currently recruiting now. Last updated 15 June 2025.

Last reviewed 2025-06-15 · How we verify

NCT06954246

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 3, Multicenter, Randomized, Open-label Study of MHB088C for Injection Versus Treatment of Physician's Choice (TPC) in Comparing the Efficacy and Safety in Subjects With Relapsed Small Cell Lung Cancer (SCLC)

Recruiting now Phase 3 Last updated 15 June 2025

What this trial tests

Phase 3 trial testing MHB088C for Injection in Small Cell Lung Cancer Extensive Stage in 450 participants. Currently enrolling.

Timeline

4 June 2025

Primary endpoint
1 May 2027

1 April 2028

Quick facts

Lead sponsor	Qilu Pharmaceutical Co., Ltd.
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	450
Start date	4 June 2025
Primary completion	1 May 2027
Estimated completion	1 April 2028
Sites	1 location across China

Drugs / interventions tested

MHB088C for Injection
Topotecan (topotecan) — full drug profile →
Irinotecan (irinotecan) — full drug profile →
Paclitaxel — full drug profile →

Conditions studied

Small Cell Lung Cancer Extensive Stage — all drugs for Small Cell Lung Cancer Extensive Stage →

Sponsor

Qilu Pharmaceutical Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Small Cell Lung Cancer Extensive Stage. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Overall Survival
Time frame: From the date of randomization to the date of death due to any cause, up to approximately 5 years

Sponsor's own description

This study was designed to compare the efficacy and safety of MHB088C for Injection with treatment of physician's choice (TPC) in participants with relapsed small cell lung cancer (SCLC).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Immunotherapy for small cell lung cancer: current challenges and prospects.
Zhong J, Jie G, Qin H, Li H, et al · · 2025 · cited 2× · PMID 41194225 · DOI 10.1186/s40164-025-00720-w
Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs.
Wu D, Yang K, He R, Yin R, et al · · 2025 · cited 2× · PMID 41133214 · DOI 10.3389/fcell.2025.1669592

Verify or expand the search:

Other trials of MHB088C for Injection

Trials testing the same drug.

NCT05652855 — Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors · Phase 1, PHASE2 · not yet recruiting

Other recruiting trials for Small Cell Lung Cancer Extensive Stage

Currently open trials in the same condition.

NCT07227597 — A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6 · Phase 1, PHASE2 · recruiting
NCT07139990 — Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) · Phase 1 · recruiting
NCT06348797 — Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC · Phase 1 · recruiting
NCT06739928 — Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC · Phase 2 · recruiting
NCT06429696 — PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer · Phase 2 · recruiting

Other Qilu Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT07511647 — A Phase 3 Clinical Study of QL2106 Injection · Phase 3 · not yet recruiting
NCT07467629 — QLS5212 for Participants With Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT07455006 — Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients · Phase 3 · not yet recruiting
NCT07463573 — QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma · Phase 3 · not yet recruiting
NCT07444086 — QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06954246 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Qilu Pharmaceutical Co., Ltd.
Last refreshed: 15 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06954246.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing